ACLS
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Moon, Y.
Right arrow Articles by Han, K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Moon, Y.
Right arrow Articles by Han, K.
Annals of Clinical & Laboratory Science 34:410-415 (2004)
© 2004 Association of Clinical Scientists

Plasma Soluble Interleukin-2 Receptor (sIL-2R) Levels in Patients with Acute Leukemia

Yeonsook Moon2, Yonggoo Kim1, Myungshin Kim1, Jihyang Lim1, Chang Suk Kang1, Won Il Kim1, Sang In Shim1, Nak Gyun Chung3, Yoon Hee Park4, Woo Sung Min4 and Kyungja Han1
1 Department of Clinical Pathology, Catholic University Medical College, Seoul; 2 Department of Laboratory Medicine, Inha University Medical College, Incheon; 3 Department of Pediatrics and 4 Department of Internal Medicine, Catholic University Medical College, Seoul, Korea

Address correspondence to Kyungja Han, M.D.; #62, Youido-dong, Youngdeungpo-gu, St. Mary’s Hospital; Department of Clinical Pathology, College of Medicine, The Catholic University of Korea, Seoul, Korea 150-713; tel 82 2 3779 1310; fax 82 2 783 6648; e-mail: hankja{at}catholic.ac.kr.

The plasma soluble interleukin-2 receptor (sIL-2R) level was higher in 137 patients with acute leukemia (1,489 ± 1,798U/ml, including 98 cases of acute myeloid leukemia (AML), 1,063 ± 1,414 U/ml, and 39 cases of acute lymphoblastic leukemia (ALL), 2,561 ± 2,194 U/ml), compared to 49 normal control subjects, 421±151 U/ml). The ALL patients showed elevated plasma sIL-2R levels more frequently than the AML patients (92.3% vs 44.9%). No patient with either hypoplastic AML or AML with multilineage dysplasia and only 1 of 13 patients with acute promyelocytic leukemia (APL) had an elevated plasma sIL-2R level. All the My+ ALL patients (15 cases) showed elevated plasma sIL-2R levels. Plasma sIL-2R levels were significantly lower after chemotherapy in the ALL patients, but were not significantly lower in the AML patients. IL-2R was expressed on the leukemic cells in 36 (53.7%) of 67 AML and in 9 (21.4%) of 42 ALL cases. None of the AML M3, M4, M5, M6, or M7 subgroups showed IL-2R expression. The My+ ALL patients (42.9%, 6/14) showed IL-2R expression more frequently than the other ALL subgroups (10.7%, 3/28) (p = 0.025). The plasma sIL-2R level was correlated with the proportion of leukemic cells expressing IL-2R in acute leukemia. However, there were many cases, particularly ALL cases, who had elevated plasma sIL-2R levels without IL-2R expression on their leukemic cells. These results suggest that the plasma sIL-2R level is a valuable marker for monitoring ALL after chemotherapy, particularly in My+ ALL cases, and that the T cell immune reaction to leukemia appears to be much higher in ALL patients than in AML patients.

Keywords: soluble interleukin-2 receptor (sIL-2R), acute myelocytic leukemia (AML), acute lymphoblastic leukemia (ALL)




This article has been cited by other articles:


Home page
 Annals of Clinical & Laboratory ScienceHome page
W. Lee, S. J. Kim, S. Lee, J. Kim, M. Kim, J. Lim, Y. Kim, B. Cho, E. J. Lee, and K. Han
Significance of Cerebrospinal Fluid sIL-2R Level as a Marker of CNS Involvement in Acute Lymphoblastic Leukemia
Ann. Clin. Lab. Sci., October 1, 2005; 35(4): 407 - 412.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the Association of Clinical Scientists.